Chemistry technology company Alexium International believes FY22 is a pivotal year for the company with the technical and commercial developments instituted by new management since 2018 now bearing fruit.
Releasing the company activities report for the quarter ended 30 September CEO Dr Bob Brookins said sales reached US$2.6 million in the quarter, an 80 per cent rise over the previous corresponding period, as sales increased of recently introduced products and new product applications were opening up.
The company’s lead BioCool fabric chemicals enjoyed their highest sales versus its traditional bedding flame retardant product.
The BioCool line are proprietary biodegradable phase change materials which add a cooling effect to fabrics such as ticking, Manchester and mattresses.
The company also announced the commercialisation of its Eclipsys cooling chemical (pictured) for the body armour market now timed for the second quarter.
Dr Brookins said recent growth has positioned the company for profitability.
He said: “The more significant point in my opinion is the success of the technical/commercial strategies that we have developed over the past few years.
“Whether relieving the thermal stress of body armour with Eclipsys or driving the removal of hazardous fibreglass from mattresses by replacing them with Alexiflam NF treated cotton…Alexium technologies can be integrated to improve the comfort and safety of these goods.”
Picture: Alexium International/Eclipsys
Subscribe to our free @AuManufacturing newsletter here.